LOGIN  |  REGISTER
FILTER BY TOPIC:     Enrollment   Pre-Clinical   First Dose   Phase 1   Phase 1/2   Phase 2   Phase 2/3   Phase 3  

Novo Nordisk: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence...

January 17
Last Trade: 78.77 -4.30 -5.18

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo,...Read more


Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

January 16
Last Trade: 9.88 -0.09 -0.90

ADDIS ABABA, Ethiopia and KINSHASA, Democratic Republic of the Congo and WASHINGTON and PARIS, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Africa CDC’s support for the MOSA, a pan-African randomized platform adaptive trial for the MpOx Study, adding to the initial EU funding, has enabled the...Read more


Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of...

January 16
Last Trade: 1.45 -0.21 -12.65

Company on track to report topline data in first half of 2025 Positive preliminary data from all five single ascending dose (SAD) cohorts ranging from 15mg to 450mg support safety and tolerability of PALI-2108 Continued progress toward Phase 1b/2a of PALI-2108 trial for the...Read more


AstraZeneca: DATROWAY® (datopotamab deruxtecan-dlnk) approved in the US for patients with previously treated metastatic...

January 17
Last Trade: 66.60 -0.31 -0.46

First approval in the US for AstraZeneca and Daiichi Sankyo’s DATROWAY based on TROPION-Breast01 results showing 37% reduction in the risk of disease progression or death vs. chemotherapy DATROWAY is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030 WILMINGTON, Del....Read more


AstraZeneca: CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously...

January 17
Last Trade: 66.60 -0.31 -0.46

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone First and only BTK inhibitor approved for the 1st-line treatment of MCL in the US WILMINGTON, Del. / Jan 17, 2025 / Business Wire / AstraZeneca’s...Read more


Amgen: FDA Approves Lumakras® (Sotorasib) in Combination with Vectibix® (Panitumumab) for Chemorefractory Kras...

January 17
Last Trade: 272.11 2.68 0.99

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in...Read more


Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. The company's lead cell therapy asset is NXC-201 in multiple myeloma...

CLICK TO LEARN MORE

Biggest Gainers

 
CompanyChangeLast Trade
Madrigal Pharmaceuticals 20.85 7.64 $293.64
Agilent Technologies 11.26 8.27 $147.36
Intuitive Surgical 8.56 1.47 $592.64
Humana 6.83 2.48 $282.63
Semler Scientific 6.44 11.06 $64.68
Blueprint Medicines 6.10 5.87 $110.05
Vertex Pharmaceuticals 5.04 1.21 $422.00
MoonLake Immunotherapeutics 4.29 10.34 $45.76
Inspire Medical Systems 3.85 2.21 $177.68
Molina Healthcare 3.61 1.28 $286.21
Krystal Biotech 3.58 2.47 $148.39
Accolade 3.45 100.29 $6.89
Sonendo 3.27 1,421.74 $3.50
Belite Bio 3.17 5.98 $56.21
Cigna 3.02 1.07 $283.99
Insulet 2.95 1.08 $275.81
Rigel Pharmaceuticals 2.78 16.02 $20.13
Vericel 2.72 4.83 $59.07

Highest Volume

 
CompanyVolumeLast Trade
AEON Biopharma 140,369,555 $0.14
Electromedical Technologies 136,407,349 $0.00
Aclarion 84,806,159 $0.04
Tonix Pharmaceuticals 37,918,406 $0.24
Aditxt 36,489,487 $0.13
Eyenovia 33,535,056 $0.06
Pfizer 31,348,496 $26.30
Walgreens Boots Alliance 28,352,948 $12.45
BioLineRx 25,604,071 $0.10
Channel Therapeutics 24,846,854 $1.91
Quantum-Si 22,450,948 $2.25
Novo Nordisk 20,089,011 $78.77
Senseonics 19,034,579 $0.85
Merck 14,885,567 $97.92
CNS Pharmaceuticals 14,815,455 $0.10
iSpecimen 14,680,787 $2.45
Conduit Pharmaceuticals 13,010,547 $0.07
CVS Health 11,879,508 $52.62
ImmunityBio 11,639,190 $2.94
  • Upcoming FDA Catalysts

    • Axsome Therapeutics (NASDAQ: AXSM) PDUFA Date

      January 25, 2025
    • Vertex Pharmaceuticals (NASDAQ: VRTX) PDUFA Date

      January 30, 2025
    • Supernus Pharmaceuticals (NASDAQ: SUPN) PDUFA Date

      February 1, 2025
    • Merus (NASDAQ: MRUS) PDUFA Date

      February 4, 2025
    • Bristol-Myers Squibb (NYSE: BMY) PDUFA Date

      February 28, 2025
    • Eton Pharmaceuticals (NASDAQ: ETON) PDUFA Date

      February 28, 2025

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including a small-molecule GLP-1 receptor...

CLICK TO LEARN MORE

Featured Stock

Surmodics

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders, with three compounds currently in clinical trials. Viking’s research and development activities leverage...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Invest In Early-Stage Biotech Opportunities

  • Explore venture capital investment opportunities in the healthcare industry and gain direct access to deal flows

  • Private placement shares can generally be purchased at a discount to market prices and have purchase warrants attached to them

  • If the underlying share price rises, warrants can be exercised to further build positions and enhance gains

  • Sign up to receive notifications of future early-stage investment opportunities:
Edit